Literature DB >> 30670537

When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression.

Giovanni Palladini1, Giampaolo Merlini1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30670537      PMCID： PMC6341187          DOI： 10.1182/bloodadvances.2018021253

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  18 in total

1.  The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

Authors:  Giovanni Palladini; Alessandra Barassi; Catherine Klersy; Rosana Pacciolla; Paolo Milani; Gabriele Sarais; Stefano Perlini; Riccardo Albertini; Paola Russo; Andrea Foli; Letizia Zenone Bragotti; Laura Obici; Remigio Moratti; Gian Vico Melzi d'Eril; Giampaolo Merlini
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

2.  Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.

Authors:  Sabrina Browning; Karen Quillen; J Mark Sloan; Gheorghe Doros; Shayna Sarosiek; Vaishali Sanchorawala
Journal:  Blood       Date:  2017-07-11       Impact factor: 22.113

3.  Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.

Authors:  Yi L Hwa; Rahma Warsame; Morie A Gertz; Francis K Buadi; Martha Q Lacy; Shaji K Kumar; David Dingli; Steve R Zeldenrust; Nelson Leung; Susanne R Hayman; Prashant Kapoor; Wilson I Gonsalves; Taxiarchis V Kourelis; Stephen Russell; Ronald S Go; Miriam A Hobbs; Amie L Fonder; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Blood       Date:  2017-08-14       Impact factor: 22.113

4.  The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response.

Authors:  Surbhi Sidana; Nidhi Tandon; Angela Dispenzieri; Morie A Gertz; S Vincent Rajkumar; Shaji K Kumar
Journal:  Leukemia       Date:  2018-01-30       Impact factor: 11.528

5.  Opening a can of worms in AL progression.

Authors:  Angela Dispenzieri
Journal:  Blood       Date:  2018-02-01       Impact factor: 22.113

6.  Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.

Authors:  Eli Muchtar; Angela Dispenzieri; Nelson Leung; Martha Q Lacy; Francis K Buadi; David Dingli; Martha Grogan; Suzanne R Hayman; Prashant Kapoor; Yi Lisa Hwa; Amie Fonder; Miriam Hobbs; Rajshekhar Chakraborty; Wilson Gonsalves; Taxiarchis V Kourelis; Rahma Warsame; Stephen Russell; John A Lust; Yi Lin; Ronald S Go; Steven Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar; Morie A Gertz
Journal:  Leukemia       Date:  2018-02-20       Impact factor: 11.528

7.  A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.

Authors:  Giovanni Palladini; Ute Hegenbart; Paolo Milani; Christoph Kimmich; Andrea Foli; Anthony D Ho; Marta Vidus Rosin; Riccardo Albertini; Remigio Moratti; Giampaolo Merlini; Stefan Schönland
Journal:  Blood       Date:  2014-08-12       Impact factor: 22.113

8.  Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.

Authors:  H Landau; H Hassoun; M A Rosenzweig; M Maurer; J Liu; C Flombaum; C Bello; E Hoover; E Riedel; S Giralt; R L Comenzo
Journal:  Leukemia       Date:  2012-09-27       Impact factor: 11.528

9.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

10.  Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.

Authors:  John R Mills; Mindy C Kohlhagen; Surendra Dasari; Patrick M Vanderboom; Robert A Kyle; Jerry A Katzmann; Maria A V Willrich; David R Barnidge; Angela Dispenzieri; David L Murray
Journal:  Clin Chem       Date:  2016-08-18       Impact factor: 8.327
View more
  7 in total

1.  Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.

Authors:  Elaine C Chen; Samuel Rubinstein; Cinque Soto; Robin G Bombardi; Samuel B Day; Luke Myers; Alexey Zaytsev; Mahsa Majedi; R Frank Cornell; James E Crowe
Journal:  PLoS One       Date:  2020-07-07       Impact factor: 3.240

Review 2.  Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.

Authors:  Shayna Sarosiek; Vaishali Sanchorawala
Journal:  J Blood Med       Date:  2019-10-23

3.  Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients.

Authors:  Alissa Visram; Abdullah S Al Saleh; Harsh Parmar; Jennifer S McDonald; John C Lieske; Iuliana Vaxman; Eli Muchtar; Miriam Hobbs; Amie Fonder; Yi L Hwa; Francis K Buadi; David Dingli; Martha Q Lacy; Angela Dispenzieri; Prashant Kapoor; Suzanne R Hayman; Rahma Warsame; Taxiarchis V Kourelis; Mustaqeem Siddiqui; Wilson I Gonsalves; John A Lust; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz; Shaji K Kumar; Nelson Leung
Journal:  Blood Cancer J       Date:  2020-12-11       Impact factor: 11.037

4.  Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.

Authors:  Gareth J Morgan; Joel N Buxbaum; Jeffery W Kelly
Journal:  Hemato       Date:  2021-10-05

Review 5.  The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis.

Authors:  Isabelle Lousada
Journal:  Orphanet J Rare Dis       Date:  2020-09-29       Impact factor: 4.123

6.  Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).

Authors:  Vincenzo Sammartano; Elisabetta Antonioli; Gabriele Buda; Sara Ciofini; Veronica Candi; Ludovica Pengue; Maria Livia Del Giudice; Irene Attucci; Francesca Bacchiarri; Ubaldo Occhini; Maria Teresa Pirrotta; Federico Perfetto; Monica Bocchia; Alessandro Gozzetti
Journal:  J Pers Med       Date:  2022-03-17

Review 7.  Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.

Authors:  Efstathios Kastritis; Ashutosh Wechalekar; Stefan Schönland; Vaishali Sanchorawala; Giampaolo Merlini; Giovanni Palladini; Monique Minnema; Murielle Roussel; Arnaud Jaccard; Ute Hegenbart; Shaji Kumar; Maria T Cibeira; Joan Blade; Meletios A Dimopoulos
Journal:  Br J Haematol       Date:  2020-07-04       Impact factor: 8.615
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.